

sigma-tau

FINANZIARIA

By facsimile & mail

vs. riferimento

ns. riferimento 437/MB/lw

roma 10 October 1989

Mr. S.R. Burzynski, M.D. Ph.D.
Burzynski Research Institute, Inc.
6221 Corporate Drive
HOUSTON
Texas 77036
U.S.A.

Dear Dr. Burzynski,

Dr. Nava sent me a copy of your letter dated October 26, 1989. It was certainly our intention to follow up our conversations of June and July earlier than this time. However, the time elapse has not been sufficient for us to take an official position vis-a-vis the scientific and marketing opportunity that we discussed.

After our latest exchange of views in person and in writing, we have continued to closely examine the option to include the United States in our prospective market for the Anti-neoplastons. A substantial amount of time and labour (including external consultants) have been invested and are actually being invested in order to determine if we can commit ourselves to the development and registration of the above-mentioned substances for the U.S. market also.

Our investigation has been focused, inter alia, on two aspects, one being the assessment of the patent status of the two compounds in question in the U.S. (we expect to receive the final outcome from our patent experts in the next few days) and the second aspect being the study of the "rapport" developed so far between the Anti-neoplastons (and Burzynski Research Institute) and the F.D.A..

We think that the "issue" here, is indeed, to verify if there is a likelihood that we can openly and effectively work with the F.D.A. in pursuing an NDA in a reasonably short period of time.

Needless to say, we are very interested in the opportunity that you are offering us. Though we are certainly willing to take some risks, we feel however that the essential premise is to know as to whether there is enough ground to bring our investments to a successful conclusion.

Our new tel. no. is: (06) 5413671

sigma-tau
FINANZIARIA


- 2 -

I can confirm that by the end of October, we should be able to give you our final position as to the direct involvement of Sigma-Tau in the development of Anti-neoplastons in the U.S.

Of course, we do not intend to ask you to wait any longer before committing yourself to another company. I am sure, however, that you appreciate our way of proceeding. In particular, we are investing time and money to try to reach a final, well-grounded conviction which should give you a guarantee as to the reliability of our commitment in the case of confirmation of our interest.

If you have any queries or comments, please do not hesitate to contact me. I shall be in touch with you again hopefully before the end of October, as previously indicated.

In the meantime, please accept my best personal regards,


Mauro Bova
Director, Corporate Affairs